Triple Combination Therapy of CDK4/6 Inhibitors, Endocrine Therapy, and mTOR/PI3K Inhibitors to Treat Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer with Acquired Resistance
Rebecca Waugh Background: In America breast cancer is the most frequently diagnosed malignancy in women2,5. Hormone receptor-positive human epidermal growth factor receptor-2 negative (HR+/HER2-) tumors categorize 65-70% of all cases and has one of the lowest survival rates1,2. Recent meta-analysis incorporate modulation CDK 4/6 inhibitors (CDKi) with endocrine therapy as…